Table 3.
Chemoradiotherapy-related acute adverse events in the matched cohort
| Adverse event | Docetaxel group [cases (%)] | Cisplatin group [cases (%)] | P value | ||
|---|---|---|---|---|---|
| Grade 1–2 | Grade 3 | Grade 1–2 | Grade 3 | ||
| Leucopenia | 90 (40.2) | 5 (2.2) | 164 (73.2) | 26 (11.6) | < 0.001 |
| Anemia | 55 (24.6) | 0 | 105 (46.8) | 2 (0.9) | < 0.001 |
| Thrombocytopenia | 3 (1.3) | 0 | 41 (18.3) | 4 (1.8) | < 0.001 |
| ALT elevation | 42 (18.8) | 1 (0.4) | 68 (30.4) | 2 (0.9) | 0.027 |
| CCR elevation | 4 (1.8) | 0 | 33 (14.7) | 1 (0.4) | < 0.001 |
| Vomitinga | 42 (18.8) | 0 | 185 (82.5) | 13 (5.8) | < 0.001 |
| Mucositisa | 45 (20.1) | 167 (74.5) | 102 (45.5) | 85 (37.9) | < 0.001 |
| Weight lossa | 171 (76.3) | 0 | 166 (74.1) | 2 (0.1) | 0.010 |
| Radiodermatitisa | 191 (85.3) | 15 (6.7) | 185 (82.6) | 4 (1.8) | 0.001 |
| Tinnitusa | 23 (10.3) | 0 | 24 (10.7) | 0 | 0.835 |
| Xerostomiaa | 171 (76.3) | 2 (0.1) | 170 (75.9) | 2 (0.1) | 0.052 |
Only one patient in the cisplatin group had grade 4 radiodermatitis
ALT Alanine transaminase, AST aspartate aminotransferase, CCR creatinine clearance
aMissing value: In the docetaxel group, medical records of 10 patients were missing for radiodermatitis, mucositis, and xerostomia, 8 for vomiting, 6 for weight loss, and 12 for tinnitus; In the cisplatin group, medical records of 35 patients were missing for radiodermatitis, 37 for mucositis, 38 for xerostomia, 9 for vomiting, 17 for weight loss, and 38 for tinnitus